Advertisement

Journal of Anesthesia

, Volume 23, Issue 1, pp 46–50 | Cite as

The effect of oral and IV ramosetron on postoperative nausea and vomiting in patients undergoing gynecological laparoscopy with total intravenous anesthesia

  • Dongchul Lee
  • Ji Young Kim
  • Jin Woo Shin
  • Chun Hoe Ku
  • Yeon Soo Park
  • Hyun Jeong Kwak
Original Article

Abstract

Purpose

Ramosetron can be administered orally as well as intravenously. We investigated the effect of oral ramosetron on postoperative nausea and vomiting (PONV) in patients undergoing gynecological laparoscopy.

Methods

One hundred and twenty women were allocated randomly to one of three groups (n = 40 in each) to receive saline (control), 0.1 mg oral ramosetron (PO), or 0.3 mg IV ramosetron (IV). Total intravenous anesthesia (TIVA) with propofol and remifentanil was used in all patients.

Results

The incidence of complete response (no PONV, no rescue) in the control, IV, and PO groups was: 65%, 90%, and 87.5%, respectively, during the first 1 h; and 67.5%, 87.5%, and 80%, respectively, during 1 to 24 h.

Conclusion

The effect of oral ramosetron 0.1 mg was comparable to that of IV ramosetron 0.3 mg on the prevention of PONV in women undergoing gynecological laparoscopy with TIVA. Both the oral and IV forms were effective at preventing PONV during the first 1 h after surgery.

Key words

Gynecological laparoscopy Postoperative nausea and vomiting Ramosetron 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Madej TH, Simpson KH. Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting following major gynecological surgery. Br J Anaesth. 1986;58:884–887.PubMedCrossRefGoogle Scholar
  2. 2.
    Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology. 1992;77:162–184.PubMedCrossRefGoogle Scholar
  3. 3.
    McCollum JS, Milligan KR, Dundee JW. The antiemetic action of propofol. Anaesthesia. 1988;43:239–240.PubMedGoogle Scholar
  4. 4.
    Smith I, White PF, Nathanson M, Gouldson R. Propofol. An update on its clinical use. Anesthesiology. 1994;81:1005–1043.PubMedCrossRefGoogle Scholar
  5. 5.
    White H, Black RJ, Jones M, Mar Fan GC. Randomized comparison of two anti-emetic strategies in high-risk patients undergoing day-case gynaecological surgery. Br J Anaesth. 2007;98:470–476.PubMedCrossRefGoogle Scholar
  6. 6.
    Fujii Y, Saitoh Y, Tanaka H, Toyooka H. Comparison of ramosetron and granisetron for preventing postoperative nausea and vomiting after gynecologic surgery. Anesth Analg. 1999;89:476–479.PubMedCrossRefGoogle Scholar
  7. 7.
    Watcha MF, Smith I. Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery. J Clin Anesth. 1994;6:370–377.PubMedCrossRefGoogle Scholar
  8. 8.
    Watcha MF. The cost-effective management of postoperative nausea and vomiting. Anesthesiology. 2000;92:931–933.PubMedCrossRefGoogle Scholar
  9. 9.
    Yano S, Makino K, Nakamura H, Kai Y, Morioka M, Hamada J, Kochi M, Kuratsu J. Comparative clinical study of the anti-emetic effects of oral ramosetron and injected granisetron in patients with malignant glioma undergoing ACNU chemotherapy. Neurol Med Chir (Tokyo). 2005;45:294–299.CrossRefGoogle Scholar
  10. 10.
    Fetzer SJ, Hand MC, Bouchard PA, Smith H, Jenkins MB. Evaluation of the Rhodes Index of Nausea and Vomiting for ambulatory surgery patients. J Adv Nurs. 2004;47:74–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Rhodes VA, McDaniel RW. The Index of Nausea, Vomiting, and Retching: a new format of the Index of Nausea and Vomiting. Oncol Nurs Forum. 1999;26:889–894.PubMedGoogle Scholar
  12. 12.
    Fujii Y, Tanaka H. Prevention of nausea and vomiting with ramosetron after total hip replacement. Clin Drug Iinvestig. 2003;23:405–409.CrossRefGoogle Scholar
  13. 13.
    Fujii Y, Tanaka H, Somekawa Y. A randomized, double-blind, placebo-controlled trial of ramosetron for preventing nausea and vomiting during termination of pregnancy. Int J Obstet Anesth. 2004;13:15–18.PubMedCrossRefGoogle Scholar
  14. 14.
    Fujii Y, Tanaka H, Toyooka H. Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. Can J Anaesth. 1994;41:794–797.PubMedGoogle Scholar
  15. 15.
    Lee HJ, Kwon JY, Shin SW, Kim CH, Baek SH, Baik SW, Kim HK, Kim KH. Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients. Eur J Anaesthesiol. 2008;25:756–762.PubMedCrossRefGoogle Scholar
  16. 16.
    Rhodes VA, Watson PM, Johnson MH. Development of reliable and valid measures of nausea and vomiting. Cancer Nurs. 1984;7:33–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Tramèr M, Moore A, McQuay H. Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies. Br J Anaesth. 1997;78:247–255.PubMedGoogle Scholar
  18. 18.
    Apfel CC, Kranke P, Katz MH, Goepfert C, Papenfuss T, Rauch S, Heineck R, Greim CA, Roewer N. Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design. Br J Anaesth. 2002;88:659–668.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Society of Anesthesiologists 2009

Authors and Affiliations

  • Dongchul Lee
    • 1
  • Ji Young Kim
    • 2
  • Jin Woo Shin
    • 3
  • Chun Hoe Ku
    • 3
  • Yeon Soo Park
    • 1
  • Hyun Jeong Kwak
    • 1
  1. 1.Department of Anesthesiology and Pain Medicine, Gil Medical CenterGachon University of Medicine and ScienceIncheonKorea
  2. 2.Department of Anesthesiology and Pain MedicineYonsei University College of MedicineSeoulKorea
  3. 3.Department of Obstetrics and Gynecology, Gil Medical CenterGachon University of Medicine and ScienceIncheonKorea

Personalised recommendations